Efficacy of the Versatis- lignocaine patch in patients with non-postherpetic neuropathic pain

Saravanakumar Kanakarajan, Kay Davies

Research output: Contribution to journalAbstract

Abstract

Background
The use of the 5% lignocaine medicated patch, Versatis®, is restricted to treatment of postherpetic neuralgia in NHS Scotland. Potentially patients with other causes of neuropathic pain may benefit from Versatis®. We aimed to review the efficacy of Versatis® in patients, with non-postherpetic neuropathic pain, attending the chronic pain service at our institution.
Methods
From February to September 2010, patients with symptoms of neuropathic pain, amenable to topical therapy, were treated with Versatis®. At their baseline visit, each patient completed a Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire and a Brief Pain Inventory (BPI). Only scores examining the effect of pain on activities of daily living (general activity, mood, walking ability, normal work, relations with others, sleep and enjoyment of life) were recorded. At 4 month follow-up, patients repeated the BPI. Patient Global Impression of Change (PGIC) and percentage pain relief were also recorded.
Results
Results of 10 patients of mean(± SD) age 64.7(±11.6) years were analysed. Median(range) S-LANSS score was 14(2-18). At 4 months follow-up, the most frequent PGIC chosen was “no change”. Median(range) percentage pain relief obtained was 10(0-80)%. Although the median(range) total BPI scores examining the effect of pain on activities of daily living fell from 48(37-63) at baseline to 41(10-54) at 4 months this was not statistically significant (p=0.13). Three patients did benefit from their patch with median(range) total BPI scores reduced from 50(46-50) to 33(12-54), pain relief of 60%,70% and 80% respectively and PGIC choice of “much improved” or “very much improved”. Two of these patients had ongoing use of the patch at 4 months. The other patient discontinued the patch after 6 weeks because it had desensitised the neuropathic pain in her foot so much, that weight bearing was now possible. Two
patients developed erythema, pruritis and vesicles from the patch.
Conclusion
The use of Versatis® in our group of patients with non-postherpetic neuropathic pain showed no statistical benefit in analgesia or the effect of pain on activities of daily living. Versatis® could be trialled for patients with neuropathic pain that is non-postherpetic in origin and a 30% success rate expected.
Original languageEnglish
Article number0100
Pages (from-to)65-66
Number of pages2
JournalBritish Journal of Pain
Volume6
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Neuralgia
Lidocaine
Pain
Activities of Daily Living
Equipment and Supplies
Postherpetic Neuralgia
Aptitude
Symptom Assessment
Weight-Bearing
Scotland
Erythema
Pruritus
Chronic Pain
Analgesia
Signs and Symptoms
Walking
Foot
Sleep

Cite this

Efficacy of the Versatis- lignocaine patch in patients with non-postherpetic neuropathic pain. / Kanakarajan, Saravanakumar; Davies, Kay.

In: British Journal of Pain, Vol. 6, No. 2, 0100, 2012, p. 65-66.

Research output: Contribution to journalAbstract

Kanakarajan, Saravanakumar ; Davies, Kay. / Efficacy of the Versatis- lignocaine patch in patients with non-postherpetic neuropathic pain. In: British Journal of Pain. 2012 ; Vol. 6, No. 2. pp. 65-66.
@article{4eb4cf0f53aa42088806a9b0fcc07609,
title = "Efficacy of the Versatis- lignocaine patch in patients with non-postherpetic neuropathic pain",
abstract = "BackgroundThe use of the 5{\%} lignocaine medicated patch, Versatis{\circledR}, is restricted to treatment of postherpetic neuralgia in NHS Scotland. Potentially patients with other causes of neuropathic pain may benefit from Versatis{\circledR}. We aimed to review the efficacy of Versatis{\circledR} in patients, with non-postherpetic neuropathic pain, attending the chronic pain service at our institution.MethodsFrom February to September 2010, patients with symptoms of neuropathic pain, amenable to topical therapy, were treated with Versatis{\circledR}. At their baseline visit, each patient completed a Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire and a Brief Pain Inventory (BPI). Only scores examining the effect of pain on activities of daily living (general activity, mood, walking ability, normal work, relations with others, sleep and enjoyment of life) were recorded. At 4 month follow-up, patients repeated the BPI. Patient Global Impression of Change (PGIC) and percentage pain relief were also recorded.ResultsResults of 10 patients of mean(± SD) age 64.7(±11.6) years were analysed. Median(range) S-LANSS score was 14(2-18). At 4 months follow-up, the most frequent PGIC chosen was “no change”. Median(range) percentage pain relief obtained was 10(0-80){\%}. Although the median(range) total BPI scores examining the effect of pain on activities of daily living fell from 48(37-63) at baseline to 41(10-54) at 4 months this was not statistically significant (p=0.13). Three patients did benefit from their patch with median(range) total BPI scores reduced from 50(46-50) to 33(12-54), pain relief of 60{\%},70{\%} and 80{\%} respectively and PGIC choice of “much improved” or “very much improved”. Two of these patients had ongoing use of the patch at 4 months. The other patient discontinued the patch after 6 weeks because it had desensitised the neuropathic pain in her foot so much, that weight bearing was now possible. Twopatients developed erythema, pruritis and vesicles from the patch.ConclusionThe use of Versatis{\circledR} in our group of patients with non-postherpetic neuropathic pain showed no statistical benefit in analgesia or the effect of pain on activities of daily living. Versatis{\circledR} could be trialled for patients with neuropathic pain that is non-postherpetic in origin and a 30{\%} success rate expected.",
author = "Saravanakumar Kanakarajan and Kay Davies",
year = "2012",
doi = "10.1177/2049463712444183",
language = "English",
volume = "6",
pages = "65--66",
journal = "British Journal of Pain",
issn = "2049-4637",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Efficacy of the Versatis- lignocaine patch in patients with non-postherpetic neuropathic pain

AU - Kanakarajan, Saravanakumar

AU - Davies, Kay

PY - 2012

Y1 - 2012

N2 - BackgroundThe use of the 5% lignocaine medicated patch, Versatis®, is restricted to treatment of postherpetic neuralgia in NHS Scotland. Potentially patients with other causes of neuropathic pain may benefit from Versatis®. We aimed to review the efficacy of Versatis® in patients, with non-postherpetic neuropathic pain, attending the chronic pain service at our institution.MethodsFrom February to September 2010, patients with symptoms of neuropathic pain, amenable to topical therapy, were treated with Versatis®. At their baseline visit, each patient completed a Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire and a Brief Pain Inventory (BPI). Only scores examining the effect of pain on activities of daily living (general activity, mood, walking ability, normal work, relations with others, sleep and enjoyment of life) were recorded. At 4 month follow-up, patients repeated the BPI. Patient Global Impression of Change (PGIC) and percentage pain relief were also recorded.ResultsResults of 10 patients of mean(± SD) age 64.7(±11.6) years were analysed. Median(range) S-LANSS score was 14(2-18). At 4 months follow-up, the most frequent PGIC chosen was “no change”. Median(range) percentage pain relief obtained was 10(0-80)%. Although the median(range) total BPI scores examining the effect of pain on activities of daily living fell from 48(37-63) at baseline to 41(10-54) at 4 months this was not statistically significant (p=0.13). Three patients did benefit from their patch with median(range) total BPI scores reduced from 50(46-50) to 33(12-54), pain relief of 60%,70% and 80% respectively and PGIC choice of “much improved” or “very much improved”. Two of these patients had ongoing use of the patch at 4 months. The other patient discontinued the patch after 6 weeks because it had desensitised the neuropathic pain in her foot so much, that weight bearing was now possible. Twopatients developed erythema, pruritis and vesicles from the patch.ConclusionThe use of Versatis® in our group of patients with non-postherpetic neuropathic pain showed no statistical benefit in analgesia or the effect of pain on activities of daily living. Versatis® could be trialled for patients with neuropathic pain that is non-postherpetic in origin and a 30% success rate expected.

AB - BackgroundThe use of the 5% lignocaine medicated patch, Versatis®, is restricted to treatment of postherpetic neuralgia in NHS Scotland. Potentially patients with other causes of neuropathic pain may benefit from Versatis®. We aimed to review the efficacy of Versatis® in patients, with non-postherpetic neuropathic pain, attending the chronic pain service at our institution.MethodsFrom February to September 2010, patients with symptoms of neuropathic pain, amenable to topical therapy, were treated with Versatis®. At their baseline visit, each patient completed a Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) questionnaire and a Brief Pain Inventory (BPI). Only scores examining the effect of pain on activities of daily living (general activity, mood, walking ability, normal work, relations with others, sleep and enjoyment of life) were recorded. At 4 month follow-up, patients repeated the BPI. Patient Global Impression of Change (PGIC) and percentage pain relief were also recorded.ResultsResults of 10 patients of mean(± SD) age 64.7(±11.6) years were analysed. Median(range) S-LANSS score was 14(2-18). At 4 months follow-up, the most frequent PGIC chosen was “no change”. Median(range) percentage pain relief obtained was 10(0-80)%. Although the median(range) total BPI scores examining the effect of pain on activities of daily living fell from 48(37-63) at baseline to 41(10-54) at 4 months this was not statistically significant (p=0.13). Three patients did benefit from their patch with median(range) total BPI scores reduced from 50(46-50) to 33(12-54), pain relief of 60%,70% and 80% respectively and PGIC choice of “much improved” or “very much improved”. Two of these patients had ongoing use of the patch at 4 months. The other patient discontinued the patch after 6 weeks because it had desensitised the neuropathic pain in her foot so much, that weight bearing was now possible. Twopatients developed erythema, pruritis and vesicles from the patch.ConclusionThe use of Versatis® in our group of patients with non-postherpetic neuropathic pain showed no statistical benefit in analgesia or the effect of pain on activities of daily living. Versatis® could be trialled for patients with neuropathic pain that is non-postherpetic in origin and a 30% success rate expected.

U2 - 10.1177/2049463712444183

DO - 10.1177/2049463712444183

M3 - Abstract

VL - 6

SP - 65

EP - 66

JO - British Journal of Pain

JF - British Journal of Pain

SN - 2049-4637

IS - 2

M1 - 0100

ER -